The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...
After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...